Jamming the signal

April 10, 2018, Ludwig Maximilian University of Munich
Jamming the signal
Coronary artery plaque rupture and thrombus formation. Credit: 7activestudio/fotolia.com

The formation of blood clots in atherosclerotic arteries results in myocardial infarction and stroke. New research at LMU now demonstrates that low doses of agents developed to treat leukemia can selectively inhibit atherosclerotic plaque-induced thrombus formation.

The rupture or erosion of atherosclerotic deposits (plaques) piling up in the inner layer of arteries exposes material to the blood stream that stimulates the adhesion and aggregation of blood platelets ( and the subsequent formation of thrombi) which can precipitate heart attacks and ischemic strokes. Several proteins play key roles in this complex process, including receptors on the platelet surface that bind to plaque collagens. Professor Wolfgang Siess and his colleagues at LMU's Institute for the Prophylaxis and Epidemiology of Cardiovascular Diseases have now shown that drugs which are used for the treatment of certain forms of leukemia specifically inhibit the formation of atherosclerotic plaque-triggered thrombus formation – and they do so more effectively than the agents currently employed for this purpose. Their findings appear in the journal Blood.

Two receptors found on platelet, glycoproteins Ib and VI, are critically involved in initiating the formation of plaque-induced thrombi. Earlier work had shown that antibodies against these receptors reduce thrombus formation triggered by atherosclerotic plaques more effectively than do standard anti-platelet therapies. "Since signal transmission by these receptors is essential for platelet activation by plaques, we suspected that inhibition of the signal pathway downstream of these receptors should also effectively suppress thrombus formation," Siess explains. The LMU researchers have now confirmed this hypothesis by inhibiting an enzyme known as Bruton's tyrosine kinase (Btk). When glycoprotein Ib or VI bind to their respective ligands, Btk gets activated and triggers a signal cascade that activates platelets. Oral intake of pharmacological inhibitors of Btk, such as ibrutinib, irreversibly blocks this process. Ibrutinib is already in clinical use for the treatment of chronic lymphocytic leukemia , and recently an even more selective Btk inhibitor (acalabrutinib) has been approved by the FDA to combat other B-cell malignancies.

The new study demonstrates that ibrutinib and two of the newer Btk inhibitors (acalabrutinib and ONO/GS-4059) specifically prevent the aggregation of platelets induced by their interaction with – both under static conditions and in the presence of shear forces like those associated with arterial blood flow. Of note, inhibition of Btk had no effect on normal thrombus formation, in which platelet aggregation is stimulated in flowing blood by interaction with the collagens found in normal connective tissues. Importantly, in healthy subjects, very low doses of ibrutinib were sufficient to block plaque-induced aggregation. This is attributable to the irreversible nature of its inhibitory effect on Btk and to the fact that platelets lack nuclei and cannot synthesize new copies of the Btk protein to replace the inactivated molecules. Given the very low dose required, it should be possible to selectively inhibit Btk in platelets without compromising the functions of other cell types in which the enzyme is expressed. "As orally bioavailable Btk inhibitors selectively and more potently inhibit plaque-induced thrombus formation than the drugs now employed, we assume that they will prove to be more suitable for the prophylaxis and therapy of and ischemic stroke," says Siess. "This is a first, encouraging step towards the application of Btk inhibitors for the prevention and therapy of these cardiovascular diseases."

Explore further: Arterial thrombosis: Cloaking of collagen frees up the flow

More information: Kristina Busygina et al. Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation, Blood (2018). DOI: 10.1182/blood-2017-09-808808

Related Stories

Arterial thrombosis: Cloaking of collagen frees up the flow

June 3, 2015
Blood clots often form when lipid-rich plaques on the inner surface of arteries rupture and platelets aggregate at the site of injury. Cardiologists from Ludwig-Maximilians-Universitaet (LMU) in Munich have now compared the ...

Anticoagulants to reduce stroke risk may increase incidence of heart attacks

December 6, 2016
Medical researchers at the Ludwig Maximilian University of Munich have discovered why a new class of anticoagulants designed to reduce the risk of strokes can—in rare cases—increase the incidence of heart attacks.

Researcher identifies targets for better anti-thrombotic medicine

May 24, 2017
Blood platelets shore up open wounds and help cuts heal, but they can also cause heart attacks and strokes when a congealed ball of platelets known as a thrombus breaks free from a site of injury and gets lodged in blood ...

PCSK9 is a co-activator of platelet function beyond its role in cholesterol homeostasis

August 28, 2017
PCSK9 is a co-activator of platelet function beyond its role in cholesterol homeostasis, according to research presented at ESC Congress today. The findings suggest that PCSK9 inhibitors, a new class of cholesterol lowering ...

Lasers used to detect risk of heart attack and stroke

August 18, 2017
Patients at risk of heart attacks and strokes may be spotted earlier thanks to a diagnosis tool that uses near-infrared light to identify high-risk arterial plaques, according to research carried out at WMG, University of ...

Recommended for you

Novel genetic study sheds new light on risk of heart attack

October 12, 2018
Loss of a protein that regulates mitochondrial function can greatly increase the risk of myocardial infarction (heart attack), Vanderbilt scientists reported Oct. 3 in the journal eLife.

Researchers say ritual for orthodox Jewish men may offer heart benefits

October 11, 2018
A pilot study led by researchers at the University of Cincinnati (UC) College of Medicine suggests Jewish men who practice wearing tefillin, which involves the tight wrapping of an arm with leather banding as part of daily ...

Markers of dairy fat consumption linked to lower risk of type two diabetes

October 10, 2018
Higher levels of biomarkers of dairy fat consumption are associated with a lower risk of developing type 2 diabetes, according to new research published today in PLOS Medicine. The study, in more than 60,000 adults, was undertaken ...

Seed oils are best for LDL cholesterol

October 9, 2018
If you want to lower your low-density lipoprotein cholesterol, called LDL or, colloquially, "bad cholesterol," the research is clear about one thing: You should exchange saturated fats with unsaturated fat. If you want to ...

Micropeptide restores heart function in mice

October 9, 2018
Researchers have discovered a micropeptide molecule that can restore normal heart function in mice, according to a study in eLife.

New risk test for sepsis for heart patients

October 5, 2018
Nearly one in four deaths in people with heart failure are caused by sepsis, according to new research.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.